The prognostic value of the expression of Bcl-2, p53 and LMP-1 in patients with Hodgkin's lymphoma

This study was undertaken to evaluate the clinical significance of the expression of Bcl-2, p53 and LMP-1 in Hodgkin and Reed-Sternberg cells of patients with Hodgkin's lymphoma. The expression of these proteins in pre-treatment tissue biopsy specimens was correlated with presenting clinical features, failure-free survival (FFS) and overall survival (OS) in 83 patients with a confirmed Hodgkin's lymphoma treated in a single institution. HIV-positive patients were excluded. Patients were classified according to the International Prognostic Score (IPS) in low-risk (0-2 factors) and high-risk groups. The median age was 41 years (15-84), 41% were women, and 93% had advanced-stage disease (IIB-IVB). The expression of Bcl-2, p53 and LMP-1 was not associated with the complete remission rate, FFS or OS. The IPS risk group was the only factor significantly associated with OS. Patients with a high IPS had a lower 5 year OS (43% vs. 79%, P=0.003). The expression of Bcl-2, p53 and LMP-1 did not add prognostic information to the IPS.